University of California San Francisco (UCSF) Health has laid off dozens of researchers, chemists, and technicians vital to drug discovery efforts targeting neurodegenerative diseases such as Alzheimer’s. The abrupt staff reductions, which follow earlier cuts this year, have left several promising therapeutic advances frozen, with some projects on the verge of FDA submission now suspended indefinitely.
Union officials report that affected employees were notified of layoffs without warning, attributing the decision to a sudden budget shortfall and ongoing financial pressures at UCSF Health. The cuts have slashed departmental budgets by up to 40%, with resources redirected to Parkinson’s research, raising concerns over strategic priorities. Researchers say the loss of institutional expertise may have lasting consequences, as displaced scientists hold critical knowledge for ongoing studies.
Chey Dean, an impacted researcher, expressed fears that the layoffs would delay or even halt development of treatments for millions suffering from fatal neurological conditions. Staff noted that remaining employees now face heightened stress and increased workloads, raising the risk of errors and developmental setbacks. The layoffs have drawn criticism from unions and public health advocates, who argue that UCSF’s actions undermine its commitment to medical research and patient care.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!